Regencell Bioscience Holdings (RGC) Enterprise Value (2020 - 2025)

Regencell Bioscience Holdings has reported Enterprise Value for 6 years, with the latest figure at -$2.5 million in Q2 2025.

• For the quarter ending Q2 2025, Enterprise Value rose 68.88% year-over-year to -$2.5 million; the trailing twelve-month figure through Jun 2024 stood at -$8.0 million (up 31.4% YoY), and the FY2025 full-year result was -$2.5 million, up 68.88% from the prior year.
• Enterprise Value for Q2 2025 stood at -$2.5 million, up from -$8.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$59413.0 in Q2 2021, with the low at -$16.4 million in Q2 2022.
• Historically, Enterprise Value has averaged -$7.7 million across 5 years, with a median of -$8.0 million in 2024.
• Annual changes were most pronounced in 2021 — Enterprise Value surged 84.65% — and 2022, when it sank 27506.1%.
• Regencell Bioscience Holdings' Enterprise Value stood at -$59413.0 in 2021, then slumped by 27506.1% to -$16.4 million in 2022, then advanced by 29.24% to -$11.6 million in 2023, then soared by 31.4% to -$8.0 million in 2024, then jumped by 68.88% to -$2.5 million in 2025.
• The last three Enterprise Value figures came in at -$2.5 million (Q2 2025), -$8.0 million (Q2 2024), and -$11.6 million (Q2 2023), per Business Quant data.